Literature DB >> 10577973

Tumour necrosis factor and other cytokines in murine lupus.

A N Theofilopoulos1, B R Lawson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10577973      PMCID： PMC1766580          DOI： 10.1136/ard.58.2008.i49

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  97 in total

1.  The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells.

Authors:  W Zheng; R A Flavell
Journal:  Cell       Date:  1997-05-16       Impact factor: 41.582

2.  Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling.

Authors:  A P Cope; R S Liblau; X D Yang; M Congia; C Laudanna; R D Schreiber; L Probert; G Kollias; H O McDevitt
Journal:  J Exp Med       Date:  1997-05-05       Impact factor: 14.307

3.  IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice.

Authors:  C Haas; B Ryffel; M Le Hir
Journal:  J Immunol       Date:  1997-06-01       Impact factor: 5.422

Review 4.  Role of cytokines in rheumatoid arthritis.

Authors:  M Feldmann; F M Brennan; R N Maini
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

5.  Requirement for transcription factor NFAT in interleukin-2 expression.

Authors:  C W Chow; M Rincón; R J Davis
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

6.  Modulation of autoimmune disease in the MRL-lpr/lpr mouse by IL-2 and TGF-beta1 gene therapy using attenuated Salmonella typhimurium as gene carrier.

Authors:  M L Huggins; F P Huang; D Xu; G Lindop; D I Stott
Journal:  Lupus       Date:  1999       Impact factor: 2.911

7.  Recombinant interleukin-2 therapy of systemic lupus erythematosus in the New Zealand black/New Zealand white mouse.

Authors:  K L Owen; T Shibata; S Izui; S E Walker
Journal:  J Biol Response Mod       Date:  1989-08

8.  Interleukin 2 deficiency is a common feature of autoimmune mice.

Authors:  M J Dauphinée; S B Kipper; D Wofsy; N Talal
Journal:  J Immunol       Date:  1981-12       Impact factor: 5.422

9.  Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice.

Authors:  C Gordon; G E Ranges; J S Greenspan; D Wofsy
Journal:  Clin Immunol Immunopathol       Date:  1989-09

10.  Analysis of T cell function in autoimmune murine strains. Defects in production and responsiveness to interleukin 2.

Authors:  A Altman; A N Theofilopoulos; R Weiner; D H Katz; F J Dixon
Journal:  J Exp Med       Date:  1981-09-01       Impact factor: 14.307
View more
  22 in total

1.  MicroRNA-let-7a expression is increased in the mesangial cells of NZB/W mice and increases IL-6 production in vitro.

Authors:  Cristen B Chafin; Nicole L Regna; Rujuan Dai; David L Caudell; Christopher M Reilly
Journal:  Autoimmunity       Date:  2013-09       Impact factor: 2.815

2.  Activation-induced deaminase-deficient MRL/lpr mice secrete high levels of protective antibodies against lupus nephritis.

Authors:  Chuancang Jiang; Ming-Lang Zhao; Richard M Scearce; Marilyn Diaz
Journal:  Arthritis Rheum       Date:  2011-04

Review 3.  Genetic studies in systemic autoimmunity and aging.

Authors:  D H Kono; A N Theofilopoulos
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

4.  Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc.

Authors:  B R Lawson; G J Prud'homme; Y Chang; H A Gardner; J Kuan; D H Kono; A N Theofilopoulos
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

5.  Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis.

Authors:  Ram Raj Singh; Vijay Saxena; Song Zang; Lily Li; Fred D Finkelman; David P Witte; Chaim O Jacob
Journal:  J Immunol       Date:  2003-05-01       Impact factor: 5.422

6.  Novel treatments for systemic lupus erythematosus.

Authors:  Wen Xiong; Robert G Lahita
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-10       Impact factor: 5.346

7.  Susceptibility of T cell receptor-alpha chain knock-out mice to ultraviolet B light and fluorouracil: a novel model for drug-induced cutaneous lupus erythematosus.

Authors:  T Yoshimasu; T Nishide; N Seo; A Hiroi; T Ohtani; K Uede; F Furukawa
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

8.  In vivo tolerance breakdown with dendritic cells pulsed with U1A protein in non-autoimmune mice: the induction of a high level of autoantibodies but not renal pathological changes.

Authors:  Jau-Ling Suen; Ya-Hui Chuang; Bor-Luen Chiang
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

9.  Activation-induced deaminase heterozygous MRL/lpr mice are delayed in the production of high-affinity pathogenic antibodies and in the development of lupus nephritis.

Authors:  Chuancang Jiang; Ming Lang Zhao; Marilyn Diaz
Journal:  Immunology       Date:  2008-06-20       Impact factor: 7.397

10.  A new model of induced experimental systemic lupus erythematosus (SLE) in pigs and its amelioration by treatment with a tolerogenic peptide.

Authors:  Amir Sharabi; Molly Dayan; Heidy Zinger; Edna Mozes
Journal:  J Clin Immunol       Date:  2009-09-16       Impact factor: 8.317
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.